Results

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.

Enrolment

Eingeschlossene Patienten: 18.537 (Stand 01. Juli 2019) 
Amgevita® (Adalimumab)25
Benepali® (Etanercept)583
Cimzia® (Certolizumab)880
Enbrel® (Etanercept)2856
Erelzi® (Etanercept)164
Flixabi® (Infliximab)2
Hulio® (Adalimumab)1
Humira® (Adalimumab)2902
Hyrimoz® (Adalimumab)29
Imraldi® (Adalimumab)25
Inflectra™ (Infliximab)16
Kevzara® (Sarilumab)77
Kineret® (Anakinra)89
MabThera® (Rituximab)1461
Olumiant® (Baricitinib)276
Orencia® (Abatacept)763
Remicade® (Infliximab)762
Remsima® (Infliximab)10
Rixathon® (Rituximab)7
RoActemra® (Tocilizumab)1311
Simponi® (Golimumab)439
Xeljanz® (Tofacitinib)220
Zessly® (Infliximab)1
Kontrollen5638

Update: August 1st, 2018; enrolled patients: 17,522

Benepali® (Etanercept)   447
Cimzia® (Certolizumab)   841
Enbrel® (Etanercept) 2859
Erelzi® (Etanercept)     65
Flixabi® (Infliximab)       1
Humira® (Adalimumab) 2883
Inflectra® (Infliximab)     16
Kevzara® (Sarilumab)     20
Kineret® (Anakinra)     89
MabThera® (Rituximab)  1459
Olumiant® (Baricitinib)    167
Orencia® (Abatacept)    718
Remicade® (Infliximab)    762
Remsima® (Infliximab)       9
RoActemra® (Tocilizumab)  1260
Simponi® (Golimumab)    428
Xeljanz® (Tofacitinib)    106
Control Group  5392